




FIGURE 1





FIGURE 2



- Pembrolizumab_ aglyco-IgG1 - (G4S)₄
- H chain
GTQVQLVQSGVEVKKPGASVKVSCKASGYTFITNYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFNKRVLTITDSSITTTAYMELKSLQFDDTAVYYCA
RRDYRFDMGFYWGQGTITVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQT
YICNVNHKPSNTKVDKKVEPKSCDKTHTCTPPCAPPELLGPSVFLFPPKPKDITLMISRTPETVCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYAST
YRVVSVLTIVLHQDWLNGKEYKCKVSNKALPAPIEKITISKAKGPREPQVYTLPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSD
GSFFLYSKLTVDKSRWQQGNVFNCSVMHEALHNHYTQKSLSPKGGGGGGGGGGGGGGG
 - L chain
TGEIVLTQSPAATLSLSPGERATLSCRASKGVSTSGYSYLHWYQOKPGQAPRLLIYLA SYLESVPA RFSGSGSGTDFTLTITSSLEPEDFAVYYCQHSRDLPLTFTG
GGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSYSLSSITLSKADYEKHKVYACEVTHQGL
SSPVTKSFNRGECLE
- Atezolizumab_HC Fab-(G4S)₄
- H chain
GTEVQLVESGGGLVQPGGSLRLSCAASGFTSFDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARR
HWPGGGFYWGQGTITVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICN
VNHKPSNTKVDKKVEPKSCDKTHTLEGGGGGGGGGGGGGGG
 - L chain
TGDIMQTSPSSLSASVGDRVTITCRASQDVSTAVAWYQOKPGKAPKLLIYASFLYSGVPSRFSGSGSGTDFTLTITSSLPQEDFATYYCQQLYHPATFGQGT
KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSYSLSSITLSKADYEKHKVYACEVTHQGLSSPV
TKSFNRGECLE

FIGURE 3





FIGURE 4



- 949_aglyco-IgG1
 - H chain
GTQVQLQQSGAELVKPGASVKMSCKAFGYTFTTYPIEWMKNHGSLEWGNFHPYNDDTKYNEKFKGAKLTVEKSTTTVYLELSRLTSDDSAVYYCAR
ENYGSHGGFVYWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGTAAAGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY
ICNVNHKPSNTKVDKKVEPKSCDKTHTCTPCPCAPPELLGGPSVFLFPPKPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTY
RVVSVLTVHLHQDWLNGKEYCKVSNKALPAPIEKTIISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDG
SFFLYSKLTVDKSRWQQGNVFCFVSMHEALHNHYTQKSLSLSPKGGGGGGGGGGGGGGG
 - L chain
TGENVLTQSPAIMSASPGEKVMTMTCRASSSVISSYLHWYQQKSGASPKLWIYSTNLSAGVPDRFSGSGSTYSISLTSVEAEADAATYYCQYNGYPLTFGA
GTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSITYSLSSITLTLISKADYEKHKVYACEVTHQGLSS
PVTKSFNRGECLE
- Atezolizumab_HC Fab-(G4S)₄
 - H chain
GTEVQLVESGGGLVQPGGSLRLSCAASGFTTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRRAEDTAVYYCARR
HWPGGFDYWGQGTLLVTVSAASTKGPSVFPLAPSSKSTSGGTAAAGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN
VNHKPSNTKVDKKVEPKSCDKTHTLEGGGGGGGGGGGGGGGGGGGGGGG
 - L chain
TGDIQMTQSPSSLSASVGDRTVITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFLTITSLQPEDFATYYCQQYLYHPATFGQGT
KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSITYSLSSITLTLISKADYEKHKVYACEVTHQGLSSPV
TKSFNRGECLE

FIGURE 5




FIGURE 7




FIGURE 8

Figure 9A




Figure 9B





Figure 10A






Figure 10B




Figure 11

Figure 12A




Figure 12B




Figure 12C




Figure 12D





Figure 12E



Molecule	N-Term Fab	C-Term Fab	Valency
Bispecific 3	mAb28 (PD-1)	6068 (PD-L1)	2:2
Bispecific 5	mAb28 (PD-1); mAb1 (PD-L1) (monovalent)	n.a.	1:1

Figure 12F




Figure 12G




Figure 13A





Figure 13B






Figure 14A




Figure 14B




Figure 15A




Figure 15B




Figure 16A




Figure 16B




Figure 17A




Figure 17B




Figure 17C

Figures 17D-17F




Figure 17F

Treatment	Tumor-free/Total
IC hlgG1	0/8
Bispecific 3	3/8
KEYTRUDA	0/8
Avelumab	0/8
KEYTRUDA + Avelumab	1/8

Figures 18A-18C

Figure 18A

Cell Binding: CHO/HuPD-1




Figure 18B

Cell Binding: CHO/CyPD-1






Figure 18C


Cell Binding: CHO/MsPD-1



Cell Binding: CHO/HuPD-L1



Cell Binding: CHO/CyPD-L1



Cell Binding: A20 (Mouse)




Figure 18D

